Surgery, Renal Cancer
Conditions
Brief summary
The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.
Detailed description
The severity of perioperative immunosuppression is directly proportional to the degree of surgical stress. A series of experimental and clinical studies indicate a different effect of certain types of anesthesia on immunity. It is believed that surgical stress itself opens an opportunity for the recurrence of oncological diseases precisely due to the immunosuppressive effect. The aim of present pilot clinical study is to test a hypothesis that total intravenous anesthesia as superior to inhalational anesthesia in term of its effects on cell immunity among patients with kidney cancer.
Interventions
DRUGPropofol
Propofol will be used for anesthesia during surgery
DRUGSevoflurane
Sevoflurane will be used for anesthesia during surgery
PROCEDUREEpidural block
Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
Sponsors
Meshalkin Research Institute of Pathology of Circulation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Surgery for renal cancer * Signed informed concent
Exclusion criteria
* Propofol or sevoflurane intolerance * Contraindications for epidural anesthesia * Renal failure * Hepatic failure * Congestive heart failure * Previous hemotherapy * Hematological diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CD 16 | postoperative day 1 | NK cells expression of CD16 receptor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CD3 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD3 expression on lymphocytes measured with flow cytometry |
| CD19 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD19 expression on lymphocytes measured with flow cytometry |
| CD4 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD4 expression on lymphocytes measured with flow cytometry |
| CD45 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD45 expression on lymphocytes measured with flow cytometry |
| CD16 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD16 expression on lymphocytes measured with flow cytometry |
| CD25 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD25 expression on lymphocytes measured with flow cytometry |
| HLA-DR | Baseline, end of surgery, postoperative days 1, 3-4, 7 | HLA-DR expression on lymphocytes measured with flow cytometry |
| CD8 | Baseline, end of surgery, postoperative days 1, 3-4, 7 | CD8 expression on lymphocytes measured with flow cytometry |
Countries
Russia
Outcome results
None listed